These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19926405)

  • 41. Test uptake and hepatitis C prevalence in 5483 Danish people in drug use treatment from 1996 to 2015: a registry-based cohort study.
    Øvrehus A; Nielsen S; Hansen JF; Holm DK; Christensen P
    Addiction; 2019 Mar; 114(3):494-503. PubMed ID: 30347471
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection.
    McGovern BH; Nagami EH; Birch CE; Bowen MJ; Reyor LL; Chung RT; Kim AY
    J Infect Dis; 2009 Sep; 200(6):877-81. PubMed ID: 19673649
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treating chronic hepatitis C in recovering opiate addicts: yes, we can.
    Kreek MJ; Talal AH; Piccolo P
    Dig Liver Dis; 2009 Apr; 41(4):308-10. PubMed ID: 19233749
    [No Abstract]   [Full Text] [Related]  

  • 44. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation.
    Mukherjee S; Rogge J; Weaver L; Schafer DF
    Transplant Proc; 2003 Dec; 35(8):3042-4. PubMed ID: 14697974
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
    Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
    Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
    Neukam K; Camacho A; Caruz A; Rallón N; Torres-Cornejo A; Rockstroh JK; Macías J; Rivero A; Benito JM; López-Cortés LF; Nattermann J; Gómez-Mateos J; Soriano V; Pineda JA
    J Hepatol; 2012 Apr; 56(4):788-94. PubMed ID: 22173157
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A model for treating HCV hepatitis in patients receiving methadone maintenance therapy.
    Malnick S; Sheidvasser V; Basevitz A; Levit S
    Isr J Psychiatry Relat Sci; 2014; 51(4):303-5. PubMed ID: 25841229
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy.
    Wong GL; Chan HL; Loo CK; Hui YT; Fung JY; Cheung D; Chung C; Chim AM; Wong VW;
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1641-1647. PubMed ID: 30707777
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
    Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
    Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C.
    Matthews GV; Hellard M; Haber P; Yeung B; Marks P; Baker D; McCaughan G; Sasadeusz J; White P; Rawlinson W; Lloyd A; Kaldor J; Dore GJ;
    Clin Infect Dis; 2009 Mar; 48(5):650-8. PubMed ID: 19191653
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies.
    Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV
    Antivir Ther; 2016; 21(5):425-34. PubMed ID: 26867206
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
    Nordstrom EM; Keniston A; Baouchi F; Martinez-Camacho A
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):10-16. PubMed ID: 27755117
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.
    Iversen J; Grebely J; Topp L; Wand H; Dore G; Maher L
    J Viral Hepat; 2014 Mar; 21(3):198-207. PubMed ID: 24438681
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility.
    MacIsaac MB; Whitton B; Hubble A; Cogger S; Penn M; Weeks A; Elmore K; Pemberton D; Anderson J; Howard R; McKeever U; Papaluca T; Hellard ME; Stoove M; Wilson D; Pedrana A; Doyle J; Clark N; Holmes J; Thompson AJ
    Med J Aust; 2023 Apr; 218(6):256-261. PubMed ID: 36919230
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C.
    Reau N; Satoskar R; Te H; DeVoss A; Elsen C; Reddy G; Mohanty S; Jensen D
    Am J Gastroenterol; 2011 Mar; 106(3):452-8. PubMed ID: 21063395
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study.
    Valerio H; Alavi M; Law M; McManus H; Tillakeratne S; Bajis S; Martinello M; Matthews GV; Amin J; Janjua NZ; Krajden M; George J; Degenhardt L; Grebely J; Dore GJ
    Clin Infect Dis; 2021 Dec; 73(11):2037-2044. PubMed ID: 34107022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme.
    Chetwynd J; Brunton C; Blank M; Plumridge E; Baldwin D
    N Z Med J; 1995 Sep; 108(1007):364-6. PubMed ID: 7566775
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of hepatitis C infection in injection drug users.
    Backmund M; Meyer K; Von Zielonka M; Eichenlaub D
    Hepatology; 2001 Jul; 34(1):188-93. PubMed ID: 11431750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.